{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:55:29Z","timestamp":1793163329850,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-51807-7","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T17:21:51Z","timestamp":1724433711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Jianjiao","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghao","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-7630","authenticated-orcid":false,"given":"Qian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yechun","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7537-3619","authenticated-orcid":false,"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"51807_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri, A. et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol. Cancer 22, 40 (2023).","journal-title":"Mol. Cancer"},{"key":"51807_CR2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. Efficacy and safety of Sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J. Thorac. Oncol. 15, 1636\u20131646 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"51807_CR3","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J. Thorac. Oncol. 16, 1501\u20131511 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"51807_CR4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.21.01845","volume":"40","author":"A Passaro","year":"2022","unstructured":"Passaro, A., Brahmer, J., Antonia, S., Mok, T. & Peters, S. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J. Clin. Oncol. 40, 598\u2013610 (2022).","journal-title":"J. Clin. Oncol."},{"key":"51807_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","volume":"13","author":"MB Bernstein","year":"2016","unstructured":"Bernstein, M. B., Krishnan, S., Hodge, J. W. & Chang, J. Y. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat. Rev. Clin. Oncol. 13, 516\u2013524 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"51807_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"W Theelen","year":"2021","unstructured":"Theelen, W. et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir. Med. 9, 467\u2013475 (2021).","journal-title":"Lancet Respir. Med."},{"key":"51807_CR7","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1158\/1078-0432.CCR-23-0315","volume":"29","author":"X Zhou","year":"2023","unstructured":"Zhou, X. et al. Safety and tolerability of low-dose radiation and stereotactic body radiotherapy + sintilimab for treatment-naive stage IV PD-L1+ non-small cell lung cancer patients. Clin. Cancer Res. 29, 4098\u20134108 (2023).","journal-title":"Clin. Cancer Res."},{"key":"51807_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/sj.cr.7310017","volume":"16","author":"Y Shi","year":"2006","unstructured":"Shi, Y. et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know. Cell Res. 16, 126\u2013133 (2006).","journal-title":"Cell Res."},{"key":"51807_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","volume":"16","author":"EB Golden","year":"2015","unstructured":"Golden, E. B. et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 16, 795\u2013803 (2015).","journal-title":"Lancet Oncol."},{"key":"51807_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/1078-0432.CCR-22-2046","volume":"29","author":"AN Shoushtari","year":"2023","unstructured":"Shoushtari, A. N. et al. Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor microenvironment and clinical outcomes in anti-PD-1-resistant advanced melanoma. Clin. Cancer Res. 29, 100\u2013109 (2023).","journal-title":"Clin. Cancer Res."},{"key":"51807_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2016.25","volume":"1","author":"H Tian","year":"2016","unstructured":"Tian, H. et al. A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. Signal Transduct. Target Ther. 1, 16025 (2016).","journal-title":"Signal Transduct. Target Ther."},{"key":"51807_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01905-3","volume":"16","author":"J Ni","year":"2021","unstructured":"Ni, J. et al. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiat. Oncol. 16, 177 (2021).","journal-title":"Radiat. Oncol."},{"key":"51807_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1158\/2326-6066.CIR-20-0427","volume":"9","author":"MM Melssen","year":"2021","unstructured":"Melssen, M. M. et al. Differential expression of CD49a and CD49b determines localization and function of tumor-infiltrating CD8(+) T cells. Cancer Immunol. Res. 9, 583\u2013597 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"51807_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","volume":"46","author":"S Cheuk","year":"2017","unstructured":"Cheuk, S. et al. CD49a expression defines tissue-resident CD8(+) T cells poised for cytotoxic function in human skin. Immunity 46, 287\u2013300 (2017).","journal-title":"Immunity"},{"key":"51807_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jconrel.2024.05.010","volume":"370","author":"C Huang","year":"2024","unstructured":"Huang, C. et al. Boosting humoral and cellular immunity with enhanced STING activation by hierarchical mesoporous metal-organic framework adjuvants. J. Control Release 370, 691\u2013706 (2024).","journal-title":"J. Control Release"},{"key":"51807_CR16","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41591-020-0995-0","volume":"26","author":"JA Juno","year":"2020","unstructured":"Juno, J. A. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 26, 1428\u20131434 (2020).","journal-title":"Nat. Med."},{"key":"51807_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejca.2022.06.034","volume":"174","author":"JP Foy","year":"2022","unstructured":"Foy, J. P. et al. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1\/PD-L1 inhibitors in real-world head and neck and lung cancer patients. Eur. J. Cancer 174, 287\u2013298 (2022).","journal-title":"Eur. J. Cancer"},{"key":"51807_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2022.108556","volume":"44","author":"JP Foy","year":"2022","unstructured":"Foy, J. P. et al. Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1\/PD-L1 inhibitors. Data Brief. 44, 108556 (2022).","journal-title":"Data Brief."},{"key":"51807_CR19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"51807_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"51807_CR21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","volume":"14","author":"YL Wu","year":"2019","unstructured":"Wu, Y. L. et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J. Thorac. Oncol. 14, 867\u2013875 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"51807_CR22","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cac2.12385","volume":"42","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer Commun. 42, 1314\u20131330 (2022).","journal-title":"Cancer Commun."},{"key":"51807_CR23","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen, W. et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5, 1276\u20131282 (2019).","journal-title":"JAMA Oncol."},{"key":"51807_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638\u2013652 (2014).","journal-title":"Cancer Cell"},{"key":"51807_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00018-024-05290-4","volume":"81","author":"GY Lian","year":"2024","unstructured":"Lian, G. Y. et al. Disrupting Smad3 potentiates immunostimulatory function of NK cells against lung carcinoma by promoting GM-CSF production. Cell Mol. Life Sci. 81, 262 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"51807_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"51807_CR27","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","volume":"47","author":"RD Seban","year":"2020","unstructured":"Seban, R. D. et al. Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur. J. Nucl. Med Mol. Imaging 47, 1147\u20131157 (2020).","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"51807_CR28","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/j.cllc.2020.02.012","volume":"21","author":"T Miyawaki","year":"2020","unstructured":"Miyawaki, T. et al. Association between clinical tumor burden and efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer. Clin. Lung Cancer 21, e405\u2013e414 (2020).","journal-title":"Clin. Lung Cancer"},{"key":"51807_CR29","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1056\/NEJM198712173172501","volume":"317","author":"S Vadhan-Raj","year":"1987","unstructured":"Vadhan-Raj, S. et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N. Engl. J. Med. 317, 1545\u20131552 (1987).","journal-title":"N. Engl. J. Med."},{"key":"51807_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","volume":"8","author":"MS Anscher","year":"2022","unstructured":"Anscher, M. S. et al. Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US Food and Drug Administration Database. JAMA Oncol. 8, 232\u2013240 (2022).","journal-title":"JAMA Oncol."},{"key":"51807_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41577-021-00568-1","volume":"22","author":"UM Cytlak","year":"2022","unstructured":"Cytlak, U. M. et al. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat. Rev. Immunol. 22, 124\u2013138 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"51807_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"ME Rodriguez-Ruiz","year":"2018","unstructured":"Rodriguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C. & Demaria, S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39, 644\u2013655 (2018).","journal-title":"Trends Immunol."},{"key":"51807_CR33","doi-asserted-by":"publisher","unstructured":"Qiang M. & Zhang R. Identification of potential immune-related ceRNA regulatory network in UVB-irradiated human skin. Biotechnol. Genet. Eng. Rev. 1\u201324 https:\/\/doi.org\/10.1080\/02648725.2023.2175501 (2023).","DOI":"10.1080\/02648725.2023.2175501"},{"key":"51807_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4110\/in.2010.10.2.75","volume":"10","author":"H Kim","year":"2010","unstructured":"Kim, H., Kang, J. S. & Lee, W. J. The production IL-21 and VEGF in UVB-irradiated human keratinocyte cell line, HaCaT. Immune Netw. 10, 75\u201380 (2010).","journal-title":"Immune Netw."},{"key":"51807_CR35","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","volume":"184","author":"C Cui","year":"2021","unstructured":"Cui, C. et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 184, 6101\u201318.e13 (2021).","journal-title":"Cell"},{"key":"51807_CR36","doi-asserted-by":"publisher","first-page":"e002157","DOI":"10.1136\/jitc-2020-002157","volume":"9","author":"J Niogret","year":"2021","unstructured":"Niogret, J. et al. Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1\/PD-1 efficacy. J. Immunother. Cancer 9, e002157 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"51807_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26362-0","volume":"12","author":"JW Cho","year":"2021","unstructured":"Cho, J. W. et al. Dysregulation of T(FH)-B-T(RM) lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer. Nat. Commun. 12, 6068 (2021).","journal-title":"Nat. Commun."},{"key":"51807_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101448","volume":"5","author":"W Liu","year":"2024","unstructured":"Liu, W. et al. An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. Cell Rep. Med. 5, 101448 (2024).","journal-title":"Cell Rep. Med."},{"key":"51807_CR39","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.3389\/fimmu.2018.02654","volume":"9","author":"AE Oja","year":"2018","unstructured":"Oja, A. E. et al. Functional heterogeneity of CD4(+) tumor-infiltrating lymphocytes with a resident memory phenotype in NSCLC. Front. Immunol. 9, 2654 (2018).","journal-title":"Front. Immunol."},{"key":"51807_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cell.2016.01.002","volume":"164","author":"S Dadi","year":"2016","unstructured":"Dadi, S. et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164, 365\u2013377 (2016).","journal-title":"Cell"},{"key":"51807_CR41","doi-asserted-by":"publisher","first-page":"12306","DOI":"10.1073\/pnas.1915681117","volume":"117","author":"EC Reilly","year":"2020","unstructured":"Reilly, E. C. et al. T(RM) integrins CD103 and CD49a differentially support adherence and motility after resolution of influenza virus infection. Proc. Natl Acad. Sci. USA 117, 12306\u201312314 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"51807_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108085","volume":"32","author":"SK Bromley","year":"2020","unstructured":"Bromley, S. K. et al. CD49a regulates cutaneous resident memory CD8(+) T cell persistence and response. Cell Rep. 32, 108085 (2020).","journal-title":"Cell Rep."},{"key":"51807_CR43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/cei\/uxac045","volume":"208","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients. Clin. Exp. Immunol. 208, 316\u2013322 (2022).","journal-title":"Clin. Exp. Immunol."},{"key":"51807_CR44","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382\u2013386 (2018).","journal-title":"Nature"},{"key":"51807_CR45","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","volume":"26","author":"KC Yuen","year":"2020","unstructured":"Yuen, K. C. et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat. Med. 26, 693\u2013698 (2020).","journal-title":"Nat. Med."},{"key":"51807_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","volume":"23","author":"JD Schoenfeld","year":"2022","unstructured":"Schoenfeld, J. D. et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 23, 279\u2013291 (2022).","journal-title":"Lancet Oncol."},{"key":"51807_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","volume":"13","author":"Y Chen","year":"2020","unstructured":"Chen, Y., Gao, M., Huang, Z., Yu, J. & Meng, X. SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J. Hematol. Oncol. 13, 105 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"51807_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2003-4-5-p3","volume":"4","author":"G Dennis Jr.","year":"2003","unstructured":"Dennis, G. Jr. et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4, P3 (2003).","journal-title":"Genome Biol."},{"key":"51807_CR49","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"51807_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 1711, 243\u2013259 (2018).","journal-title":"Methods Mol. Biol."},{"key":"51807_CR51","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","volume":"184","author":"BA Luca","year":"2021","unstructured":"Luca, B. A. et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell 184, 5482\u201396.e28 (2021).","journal-title":"Cell"},{"key":"51807_CR52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-0716-2986-4_4","volume":"2629","author":"CB Steen","year":"2023","unstructured":"Steen, C. B., Luca, B. A., Alizadeh, A. A., Gentles, A. J. & Newman, A. M. Profiling cellular ecosystems at single-cell resolution and at scale with EcoTyper. Methods Mol. Biol. 2629, 43\u201371 (2023).","journal-title":"Methods Mol. Biol."},{"key":"51807_CR53","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.3390\/cancers13153678","volume":"13","author":"X Lin","year":"2021","unstructured":"Lin, X. et al. Follicular helper T cells remodel the immune microenvironment of pancreatic cancer via secreting CXCL13 and IL-21. Cancers 13, 3678 (2021).","journal-title":"Cancers"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51807-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51807-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51807-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T17:25:03Z","timestamp":1724433903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51807-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51807"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51807-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"3 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7242"}}